| Autor: |
Ataeinia B; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran., Loberg C; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany., Kravets H; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany., Beheshti M; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany., von Mallek D; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany., Mottaghy FM; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands., Heinzel A; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany. |
| Abstrakt: |
We present the case of a 77 year old male patient with metastatic pancreatic neuroendocrine tumor (NET). The patient was initially treated by extensive surgical resection that however, led to severe complications with delayed recovery. During follow-up, a number of new liver metastases were detected, one of which was in segment I with impending compression of the inferior vena cava. Due to age and general condition of the patient, instead of further surgical treatment, the patient received four cycles of 177 Lu-DOTATOC resulting in an overall partial response with successful tumor reduction in liver segment I, resolving an impending compression of vena cava. |
